AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11696618 — intervention group
Group type: COMPARATOR
Intervention: Accelerated-hyperfractionated radiotherapy (54 Gy/36 fractions/3.6 weeks) with concurrent cisplatin (80 mg/m² on day 1) and vindesine (3 mg/m² on days 1 and 8 every 4 weeks)
Number of subjects: 21
Study 9043729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg glycopyrrolate im
Number of subjects: 80
Study 9043729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg hyoscine hydrobromide po
Number of subjects: 80
Study 9043729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg hyoscine hydrobromide im
Number of subjects: 80
Study 9043729 — intervention group
Group type: COMPARATOR
Intervention: No anticholinergic
Number of subjects: 80
Study 9043729 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 8936349 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Disability Status Scale (EDSS)
Number of subjects: 48
Study 8936349 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripps Neurologic Rating Scale (SNRS)
Number of subjects: 48
Study 2407084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily (group 1, n = 115)
Number of subjects: 232
Study 2407084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2, n = 117)
Number of subjects: 232
Study 2407084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily (group 1)
Number of subjects: 232
Study 2407084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2)
Number of subjects: 232
Study 7002183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (250, 500, and 1000 mg)
Number of subjects: 0
Study 7002183 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone
Number of subjects: 0
Study 7002183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone
Number of subjects: 0
Study 7002183 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulations of Optalidon (aminopyrine replaced by propyphenazone)
Number of subjects: 0
Study 7002183 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulations of Tonopan (aminopyrine replaced by propyphenazone)
Number of subjects: 0
Study 7002183 — intervention group
Group type: COMPARATOR
Intervention: Combination of aminopyrine, caffeine, and butalbarbital (Optalidon)
Number of subjects: 0
Study 7002183 — intervention group
Group type: COMPARATOR
Intervention: Combination of aminopyrine, caffeine, butalbarbital, and dihydroergotamine (Tonopan)
Number of subjects: 0
Study 31724026 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-Duration Chemotherapy-Free Treatment
Number of subjects: 0
Study 28545978 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg injections every 4 weeks for 12 weeks
Number of subjects: 351
Study 28545978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 28545978 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 351
Study 25504861 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab
Number of subjects: 112
Study 25140772 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 60
Study 25140772 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhaled nitric oxide)
Number of subjects: 60
Study 22443353 — intervention group
Group type: EXPERIMENTAL
Intervention: ADIPOR1 SNPs (rs1342387 and rs12733285)
Number of subjects: 77
Study 22443353 — intervention group
Group type: EXPERIMENTAL
Intervention: ADIPOQ SNPs
Number of subjects: 77
Study 20102872 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemia levels categorized as < or = 100 mg/dL (5.5 mmol/L)
Number of subjects: 456
Study 20102872 — intervention group
Group type: COMPARATOR
Intervention: Patients with diabetes mellitus
Number of subjects: 456
Study 20102872 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of patients
Number of subjects: 456
Study 20102872 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned hospital admission
Number of subjects: 456
Study 18716704 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 202
Study 18716704 — intervention group
Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 202
Study 16024244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg
Number of subjects: 360
Study 16024244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg
Number of subjects: 360
Study 16024244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 11849660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (n=20)
Number of subjects: 40
Study 11849660 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (n=20)
Number of subjects: 40
Study 10065804 — intervention group
Group type: EXPERIMENTAL
Intervention: New parallel technique of Veress needle insertion (group 2; n = 100)
Number of subjects: 200
Study 10065804 — intervention group
Group type: COMPARATOR
Intervention: Conventional closed method (group 1; n = 100)
Number of subjects: 200
Study 10065804 — intervention group
Group type: EXPERIMENTAL
Intervention: New parallel technique of Veress needle insertion
Number of subjects: 200
Study 10065804 — intervention group
Group type: COMPARATOR
Intervention: Conventional closed method
Number of subjects: 200
Study 8774014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (last two movements reversed)
Number of subjects: 30
Study 8774014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (second two movements reversed)
Number of subjects: 30
Study 8774014 — intervention group
Group type: COMPARATOR
Intervention: Group III (first two movements reversed)
Number of subjects: 30
Study 1611640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 120 mg
Number of subjects: 12
Study 1611640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 240 mg
Number of subjects: 12
Study 1611640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 360 mg
Number of subjects: 12
Study 1611640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 480 mg
Number of subjects: 12
Study 6508407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic regional cytostatic perfusion with melphalan (42 C)
Number of subjects: 107
Study 6508407 — intervention group
Group type: COMPARATOR
Intervention: Control group (wide excision and lymph node dissection)
Number of subjects: 107
Study 30855449 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc
Number of subjects: 50
Study 30855449 — intervention group
Group type: COMPARATOR
Intervention: Non-polaprezinc
Number of subjects: 50
Study 30584293 — intervention group
Group type: EXPERIMENTAL
Intervention: IND/MF (QMF149) 150/160 µg once daily
Number of subjects: 629
Study 30584293 — intervention group
Group type: COMPARATOR
Intervention: Sal/Flu (50/500 µg twice daily)
Number of subjects: 629
Study 26368280 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 24
Study 26368280 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 24
Study 23352196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly
Number of subjects: 1098
Study 23352196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 1098
Study 23352196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly
Number of subjects: 1098
Study 23352196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg PRN
Number of subjects: 1098
Study 21306595 — intervention group
Group type: EXPERIMENTAL
Intervention: Current major depressive episode (MDE) at baseline
Number of subjects: 261
Study 21306595 — intervention group
Group type: COMPARATOR
Intervention: Recent (31+ days to 12 months) MDE
Number of subjects: 261
Study 21306595 — intervention group
Group type: COMPARATOR
Intervention: Past MDE at baseline
Number of subjects: 261
Study 21306595 — intervention group
Group type: EXPERIMENTAL
Intervention: Current MDE at baseline
Number of subjects: 261
Study 19290768 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic Inquiry and Word Count (LIWC)
Number of subjects: 63
Study 19290768 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric Content Analysis and Diagnosis (PCAD)
Number of subjects: 63
Study 17429201 — intervention group
Group type: EXPERIMENTAL
Intervention: IP Extra (group 1)
Number of subjects: 31
Study 17429201 — intervention group
Group type: EXPERIMENTAL
Intervention: IP Standard (group 2)
Number of subjects: 31
Study 17429201 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study 15365213 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 9
Study 15365213 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free hemodialysis (AFHD)
Number of subjects: 9
Study 15365213 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysis (BD)
Number of subjects: 9
Study 15365213 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques (AFB, AFHD, BD)
Number of subjects: 9
Study 11276406 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatments (specifics not provided)
Number of subjects: 0
Study 11276406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexperimental evidence of antidepressant use (specifics not provided)
Number of subjects: 0
Study 11276406 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive model for assessing antidepressant use in youths
Number of subjects: 0
Study 8385750 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural conjugates oestrogen (0.625 mg per diem per os) plus MAP (10 mg per diem per os) for 12 days a month
Number of subjects: 28
Study 8385750 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 28
Study 3955441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral medial rectus muscle recession without severing check ligaments
Number of subjects: 25
Study 3955441 — intervention group
Group type: COMPARATOR
Intervention: Bilateral medial rectus muscle recession with severing check ligaments
Number of subjects: 25
Study 29117990 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin (PKC412) administered daily for 4 days
Number of subjects: 0
Study 29117990 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin with ketoconazole
Number of subjects: 0
Study 29117990 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin with rifampicin
Number of subjects: 0
Study 29117990 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin with midazolam
Number of subjects: 0
Study 27638296 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 90
Study 27638296 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 90
Study 25274978 — intervention group
Group type: COMPARATOR
Intervention: 9-valent HPV vaccine (HPV6/11/16/18/31/33/45/52/58)
Number of subjects: 12614
Study 25274978 — intervention group
Group type: COMPARATOR
Intervention: HPV types (HPV35/39/51/56/59)
Number of subjects: 12614
Study 25274978 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV6/11/16/18/31/33/45/52/58
Number of subjects: 12614
Study 24423823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin, gemcitabine, paclitaxel, and pemetrexed) under the guidance of molecular markers
Number of subjects: 86
Study 24423823 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m(2) days 1 and 8 with 21 days as a cycle
Number of subjects: 86
Study 20227156 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb technique
Number of subjects: 34
Study 20227156 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique
Number of subjects: 34
Study 18849230 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal thoracic artery preparation with intact pleura (Group 1)
Number of subjects: 54
Study 16449899 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction and fusion using Harrington rods (ST)
Number of subjects: 283
Study 16449899 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment (BT)
Number of subjects: 283
Study 16449899 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 283
Study 12865036 — intervention group
Group type: EXPERIMENTAL
Intervention: Key staff turnover in the HT-CT (clinic practitioner, clinic manager, principal investigator)
Number of subjects: 0
Study 12865036 — intervention group
Group type: EXPERIMENTAL
Intervention: Key staff turnover in the DM-CT (lead nutritionist)
Number of subjects: 0
Study 12865036 — intervention group
Group type: EXPERIMENTAL
Intervention: Key staff turnover in the DM-CT and HT-CT
Number of subjects: 0
Study 11042989 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 percent CP whitening agent
Number of subjects: 57
Study 11042989 — intervention group
Group type: COMPARATOR
Intervention: 10 percent CP whitening agent
Number of subjects: 57
Study 8778601 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly scheduled inhaled albuterol
Number of subjects: 255
Study 8778601 — intervention group
Group type: COMPARATOR
Intervention: As-needed inhaled albuterol
Number of subjects: 255
Study 1462677 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (n = 6)
Number of subjects: 54
Study 1462677 — intervention group
Group type: EXPERIMENTAL
Intervention: D-alpha-tocopherol (n = 6)
Number of subjects: 54
Study 1462677 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (n = 6)
Number of subjects: 54
Study 1462677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (n = 6)
Number of subjects: 54
Study 1462677 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet light exposure (n = 24)
Number of subjects: 54
Study 1462677 — intervention group
Group type: COMPARATOR
Intervention: Sunbathing (n = 8)
Number of subjects: 54
Study 2875904 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate (12 mg twice daily in sustained release form)
Number of subjects: 16
Study 2875904 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 16
Study 31631788 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed training schedule
Number of subjects: 23
Study 31631788 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed training schedule
Number of subjects: 23
Study 31631788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid training schedule 1
Number of subjects: 23
Study 31631788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid training schedule 2
Number of subjects: 23
Study 31631788 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 29857773 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 49
Study 29857773 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) smoking cessation services
Number of subjects: 49
Study 27596557 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-J stent indwelling for 7 days
Number of subjects: 142
Study 27596557 — intervention group
Group type: COMPARATOR
Intervention: Double-J stent indwelling for > 7 days
Number of subjects: 142
Study 27596557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study 24115082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg every 2 weeks (q2w)
Number of subjects: 32
Study 24115082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 162 mg weekly (qw)
Number of subjects: 32
Study 24115082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab 81 mg every 2 weeks (q2w)
Number of subjects: 32
Study 22152401 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy (SET)
Number of subjects: 156
Study 22152401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy + clinical management (MED)
Number of subjects: 156
Study 22152401 — intervention group
Group type: COMPARATOR
Intervention: Pill-placebo + clinical management (PBO)
Number of subjects: 156
Study 21636321 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week passive stretching program consisting of 4 hamstring and hip stretches performed 5 times per week
Number of subjects: 22
Study 21636321 — intervention group
Group type: COMPARATOR
Intervention: Non-stretching control group
Number of subjects: 22
Study 19797987 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior subfascial transposition of the ulnar nerve
Number of subjects: 117
Study 19797987 — intervention group
Group type: COMPARATOR
Intervention: In situ decompression of the ulnar nerve
Number of subjects: 117
Study 16951518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing model (increasing by 15 beats per minute on the basic rate of the mean nocturnal sinus)
Number of subjects: 16
Study 16951518 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous rhythm model
Number of subjects: 16
Study 15301658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus bupropion SR (150 mg per day)
Number of subjects: 211
Study 15301658 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch plus placebo
Number of subjects: 211
Study 12212624 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude of 2800 m for 1 h
Number of subjects: 18
Study 12212624 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude of 3600 m for 1 h
Number of subjects: 18
Study 12212624 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude of 4400 m for 1 h
Number of subjects: 18
Study 12212624 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude of 300 m (control)
Number of subjects: 18
Study 9349066 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (75 micrograms.kg‐1)
Number of subjects: 80
Study 9349066 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine (3 micrograms.kg‐1)
Number of subjects: 80
Study 9349066 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil (0.2 microgram.kg‐1)
Number of subjects: 80
Study 9349066 — intervention group
Group type: COMPARATOR
Intervention: lignocaine and bupivacaine alone
Number of subjects: 80
Study 8463436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 40
Study 8463436 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 40
Study 8463436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3896355 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus maskers
Number of subjects: 472
Study 3896355 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination instruments (masker plus hearing aid)
Number of subjects: 472
Study 3896355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 472
Study 3896355 — intervention group
Group type: COMPARATOR
Intervention: Thorough investigation and careful counselling
Number of subjects: 472
Study 3896355 — intervention group
Group type: COMPARATOR
Intervention: Audiometric and tinnitus tests
Number of subjects: 472
Study 29541962 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in Life Environments (MILE) intervention
Number of subjects: 212
Study 29541962 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 212
Study 26829370 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-neutral program
Number of subjects: 80
Study 26829370 — intervention group
Group type: COMPARATOR
Intervention: Conventional weight-management program
Number of subjects: 80
Study 23891925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg, twice daily)
Number of subjects: 43
Study 23891925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 23062530 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (moderate exercise volumes of 3 to <5 MET-h and 5 to <7 MET-h per week)
Number of subjects: 959
Study 23062530 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise volume
Number of subjects: 959
Study 20374562 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day) for 3 months
Number of subjects: 353
Study 20374562 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 3 months
Number of subjects: 353
Study 20374562 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day) for 9 months
Number of subjects: 353
Study 20374562 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 9 months
Number of subjects: 353
Study 20374562 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day)
Number of subjects: 353
Study 20374562 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 353
Study 18922495 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A nonwaterproof mascara
Number of subjects: 40
Study 18922495 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand B nonwaterproof mascara
Number of subjects: 40
Study 15807218 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg/day for 10 days
Number of subjects: 36
Study 15807218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12625969 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment (rectally for at least 4 days)
Number of subjects: 142
Study 12625969 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 142
Study 10520835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 15
Study 10520835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7496647 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20, 40, or 60 mg)
Number of subjects: 0
Study 7496647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1784590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg.3/day)
Number of subjects: 8
Study 1784590 — intervention group
Group type: COMPARATOR
Intervention: Atropine (increasing boluses)
Number of subjects: 8
Study 6807568 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 480 mg/day
Number of subjects: 26